There are now available several different recombinant factor products for the treatment of hemophilia. There are specific considerations in prescribing a product for any individual patient.

Therefore MASAC recommends that insurance companies and other third-party payers such as Medicaid, Medicare, CMS, etc. cover whichever recombinant factor product is prescribed by the patient's treating physician.

MASAC Document 153 - Recommendation Concerning Reimbursement for Recombinant Clotting Factor Concentrates
Advertisement